These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Variable reduction of caveolin-3 in patients with LGMD2B/MM. Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575 [TBL] [Abstract][Full Text] [Related]
9. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF. Diers A; Carl M; Stoltenburg-Didinger G; Vorgerd M; Spuler S Neuromuscul Disord; 2007 Feb; 17(2):157-62. PubMed ID: 17129727 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Vilchez JJ; Gallano P; Gallardo E; Lasa A; Rojas-García R; Freixas A; De Luna N; Calafell F; Sevilla T; Mayordomo F; Baiget M; Illa I Arch Neurol; 2005 Aug; 62(8):1256-9. PubMed ID: 16087766 [TBL] [Abstract][Full Text] [Related]
11. Characterisation of the dysferlin skeletal muscle promoter. Foxton RM; Laval SH; Bushby KM Eur J Hum Genet; 2004 Feb; 12(2):127-31. PubMed ID: 14560310 [TBL] [Abstract][Full Text] [Related]
12. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Nguyen K; Bassez G; Bernard R; Krahn M; Labelle V; Figarella-Branger D; Pouget J; Hammouda el H; Béroud C; Urtizberea A; Eymard B; Leturcq F; Lévy N Hum Mutat; 2005 Aug; 26(2):165. PubMed ID: 16010686 [TBL] [Abstract][Full Text] [Related]
14. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies. Piccolo F; Moore SA; Ford GC; Campbell KP Ann Neurol; 2000 Dec; 48(6):902-12. PubMed ID: 11117547 [TBL] [Abstract][Full Text] [Related]
15. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Wenzel K; Carl M; Perrot A; Zabojszcza J; Assadi M; Ebeling M; Geier C; Robinson PN; Kress W; Osterziel KJ; Spuler S Hum Mutat; 2006 Jun; 27(6):599-600. PubMed ID: 16705711 [TBL] [Abstract][Full Text] [Related]
16. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Paradas C; Llauger J; Diaz-Manera J; Rojas-García R; De Luna N; Iturriaga C; Márquez C; Usón M; Hankiewicz K; Gallardo E; Illa I Neurology; 2010 Jul; 75(4):316-23. PubMed ID: 20574037 [TBL] [Abstract][Full Text] [Related]
17. Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene. Leshinsky-Silver E; Argov Z; Rozenboim L; Cohen S; Tzofi Z; Cohen Y; Wirguin Y; Dabby R; Lev D; Sadeh M Neuromuscul Disord; 2007 Dec; 17(11-12):950-4. PubMed ID: 17825554 [TBL] [Abstract][Full Text] [Related]
18. Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells. Meregalli M; Navarro C; Sitzia C; Farini A; Montani E; Wein N; Razini P; Beley C; Cassinelli L; Parolini D; Belicchi M; Parazzoli D; Garcia L; Torrente Y FEBS J; 2013 Dec; 280(23):6045-60. PubMed ID: 24028392 [TBL] [Abstract][Full Text] [Related]
19. Proteomic investigation of the molecular pathophysiology of dysferlinopathy. De Palma S; Morandi L; Mariani E; Begum S; Cerretelli P; Wait R; Gelfi C Proteomics; 2006 Jan; 6(1):379-85. PubMed ID: 16302276 [TBL] [Abstract][Full Text] [Related]